Allergan predicts 21% to 27% jump in sales during 2006

By Angela McDaniels

Seattle, March 27 - Allergan Inc. estimated that total sales for 2006 will increase to between $2.805 billion and $2.945 billion from $2.319 billion in 2005.

In a company news release, Allergan further estimated that:

• Pharmaceutical sales for 2006 will be between $2.445 billion and $2.545 billion. Pharmaceutical sales exclude sales of products acquired in the acquisition of Inamed Corp. in December;

• Other revenue will be between $50 million and $60 million, including other revenue associated with the development and promotion arrangements with GlaxoSmithKline of between $30 million and $35 million and other revenue associated with contractual and royalty agreements of between $20 million and $25 million;

• GAAP diluted earnings for 2006 will be between $1.96 and $2.08 per share;

• Adjusted diluted earnings for 2006 will be between $3.56 and $3.62 per share;

• Total sales for the first quarter of 2006 will be between $600 million and $610 million, which excludes Inamed sales;

• GAAP diluted earnings for the first quarter of 2006 will be between $0.05 and $0.07 per share, which includes a purchase accounting adjustment of between $0.73 and $0.76 related to in-process research and development;

• Adjusted diluted earnings for the first quarter of 2006 will be between $0.80 and $0.81 per share.

Allergan is a health care company based in Irvine, Calif., that develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.